|
Note 16 - CONCENTRATIONS
|
12 Months Ended |
|---|---|
|
Dec. 31, 2013
|
|
| Notes to Financial Statements | |
| Note 16 - CONCENTRATIONS |
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
The Companys revenues earned from sale of products and services for the year ended December 31, 2013 included an aggregate of 26% from one customer of the Companys total revenues.
One customer accounted for 17% of the Companys total accounts receivable at December 31, 2013.
The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant. |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|